What "strong growth" ?
The testing services business is yet to perform. Growth is sluggish and not what was projected when it IPO'd.
The directors then decide to acquire revenue by buying a business in the UK that doesn't make a profit and to do that they do a heavily dilutive cap raising at 23 cents which was a 30% discount to the then prevailing share price.
Shareholders have been done over. The next quarterly is likely to show a continuation of big cash burn.
- Forums
- ASX - By Stock
- Ann: Completion of Autoimmune Program with Ginkgo Bioworks
MAP
microba life sciences limited
Add to My Watchlist
4.17%
!
9.2¢

What "strong growth" ?The testing services business is yet to...
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
9.2¢ |
Change
-0.004(4.17%) |
Mkt cap ! $47.38M |
Open | High | Low | Value | Volume |
9.6¢ | 9.6¢ | 9.2¢ | $11.09K | 118.8K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
5 | 20774 | 9.2¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
9.5¢ | 114482 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
5 | 20774 | 0.092 |
4 | 60967 | 0.091 |
7 | 405677 | 0.090 |
2 | 192844 | 0.089 |
2 | 12552 | 0.088 |
Price($) | Vol. | No. |
---|---|---|
0.095 | 114482 | 1 |
0.099 | 88000 | 1 |
0.100 | 100000 | 1 |
0.105 | 103000 | 1 |
0.110 | 1714 | 1 |
Last trade - 15.11pm 29/07/2025 (20 minute delay) ? |
Featured News
MAP (ASX) Chart |